Landscapes / Companies
Alto Neuroscience not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
4 in Phase 2
Drugs
4
in active trials · 5 in all
Trials
4 active
10 since 2021
Drugs4
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 2 | Dec 2026Phase 2 trial completes | |||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Major Depressive Disorder | ||||
| Open drug page | |||||
— |
Phase 2 | Sep 2027Phase 2 trial completes | |||
| Next date | Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Bipolar Disorder I or II With a Major Depressive Episode | ||||
| Open drug page | |||||
— |
Phase 2 | Nov 2027Phase 2 trial completes | |||
| Next date | Nov 2027 · Phase 2 trial completes | ||||
| Also tested for | Treatment-resistant Depression (TRD) | ||||
| Open drug page | |||||
— |
Phase 2 | — | |||
| Also tested for | Schizophrenia, Cognitive Impairment | ||||
| Open drug page | |||||
About
- No active trial
- ALTO-203
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021